While it is universally true much more attention is focused on success in clinical trials in the sense of patients who respond well to a particular therapy, this doesn’t mean we can’t learn from people who tumours either don’t respond to treatment up front or relapse early.
In our latest review, we look at three different examples of what we can learn from biomarkers of T cell exhaustion with both CAR-T cell therapies (with two different targets) as well as immune checkpoint blockade.
In short, there’s more to think about beyond antigen loss and target downregulation.
Why does this matter?
Well if we can identify markers of early relapse then we can either intervene earlier and switch to another therapy or we can add something else in to try and rescue the patient’s immune response.
Here we discuss some of the scientific findings from different research labs and explore how the information uncovered may be key to either future novel developments or clinical strategies with current immunotherapy approaches…